admin

TORONTO, Jan. 21, 2021 — CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), is pleased to release a recent interview with company Co-founder and President, Paul Ramsay, on The Wall Street Analyzer, a multi-media financial research and publishing company reporting to the investment community on publicly held companies. It can be heard in full at:https://wallstreetanalyzer.com/2020/12/23/canaquest-medical-corp-otc-canqf/Highlights in the discussion include significant milestones achieved by the Company:The Announcement that The Journal of Neuroscience has published the findings of Western University’s research leading to the discovery of Mentabinol®, a patented THC based formulation & L-theanine - a safer alternative, for people who are taking THC for mental [...]

TORONTO, Dec. 03, 2020 -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced that The Journal of Neuroscience has published the findings of Western University’s research leading to the discovery of the Mentabinol®, a patented THC based formulation & L-theanine, a compound derived from Green Tea leaves. The Journal of Neuroscience, a world leading research publication, is a weekly peer-reviewed scientific journal published by the Society for Neuroscience. It covers empirical research on all aspects of neuroscience. This research showed that when the THC based formulation was combined with the compound L-theanine it protected [...]

TORONTO – September 17, 2020 − CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced that it has been approved to raise capital on The OCMX™, an online portal that publicizes and provides financial connections to public and privately held investment opportunities. Planned use of proceeds for CanaQuest’s raise include helping further facilitate a funding pathway for FDA drug approval, which is already underway. The OCMX™ has spent considerable time completing its due diligence on the Company and concluded that there is indeed a tremendous opportunity for Investors and Advisors. The OCMX™ noted that, “CanaQuest [...]

TORONTO – July 14, 2020 − CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a company developing unique health products and nutraceuticals utilizing cannabis/hemp molecules and botanical compounds, has filed a Provisional Cannabidiol/Omega-3 Patent, trade named Mentanine®, which was developed as a result of its sponsored research program at Western University, based in London, Ontario, Canada. The application of CBD alone has little effect/impact on the ability of the Central Nervous System “CNS” to help with mental health issues. Our newly developed formula will be a “life changer” for many. The scientifically developed formula went through pre-clinical studies at Western University. Results from these pre-clinical trials, addressing anxiety, depression, PTSD, and schizophrenia [...]

Toronto, Feb. 06, 2020 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a developer of novel health products utilizing cannabis, hemp, and botanical extracts, including algae oils, today announced it has applied to Health Canada for approval to produce, sell and export Mentabinol® (THC based, all-natural formulation) under the Cannabis Act. Approval of the filed application is anticipated in March 2020 and will enable CanaQuest and its Licensed Processor partners, who are capable of formulating, processing, packaging and distribution throughout Canada to initiate sales and global exports 30 days after approval. CanaQuest was awarded a Cannabis Sales/Purchase, Import/Export license from Health Canada through its wholly owned subsidiary ADC BioMedical [...]

Phoenix, Arizona--(Newsfile Corp. - November 25, 2019) - The Stock Day Podcast welcomed CanaQuest Medical Corp. (OTC Pink: CANQF) ("the Company"), a company engaged in the development of unique health products and nutraceuticals that utilize hemp, cannabis and algae oils. Chairman and Co-Founder of the Company, Paul Ramsay, joined Stock Day host Everett Jolly.Jolly began the interview by asking about the Company's current projects. Ramsay shared that the Company recently announced the filing of an international master patent. "For this one, we're looking at a game changing discovery with Mentabinol®," said Ramsay. He further explained that Mentabinol® protects cannabis users from the negative psychoactive effects of THC. "This is going to be very impactful for [...]

Research & development is a primary focus for this medical cannabis company TORONTO − October 29, 2019 − CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”) announces that it has won the Go Global Awards "Business of the Year – Category of Life Science”, presented by the International Trade Council. The final judging took place during the Think Global Conference on October 22nd and 23rd in Chicago. This recognition will further open doors for international business opportunities. CanaQuest presented before a select judging panel and an audience of CEOs, investors and Government Ministers and Ambassadors. To view the presentation provided, visit http://nnw.fm/Go-Global-Awards-Presentation. Recently, CanaQuest was granted a cannabis sales-import-export license from Health [...]

A NOVEL BOTANICAL AND TETRAHYDROCANNABINOL (“THC”) FORMULATION FOR THE REDUCTION OF CANNABIS-INDUCED NEGATIVE NEUROPSYCHIATRIC SIDE-EFFECTS Research & development a primary focus for this medical cannabis company TORONTO – September 17, 2019 − CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a company developing unique health products and nutraceuticals utilizing cannabis and botanical oil extracts, has filed an International Cannabis/Botanical Patent which stems from its sponsored research program at Western University in London, Ontario, Canada. The use of marijuana is known to cause neuronal, molecular and neuropsychiatric side effects. This complicates the use of marijuana for medical treatment. Δ-9-tetrahydrocannabinol (THC) is the primary psychoactive compound in marijuana (MJ). As demonstrated in both clinical [...]

Licence is a foundation for the company to begin domestic and international sales of our Proprietary Cannabis and Botanical formulated products. Under the proposed Health Canada Amendment for Cannabis Edibles Regulations, our products will be included and licenced for sale as of December 17th, 2019. THC and CBD Research & Development at prestigious universities is the primary factor for the development of the Company's Products.  TORONTO, Sept. 11, 2019 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: "CANQF") (the "Company" or "CanaQuest"), a company developing proprietary health products and nutraceuticals utilizing cannabinoid and botanical oil extracts, through its wholly-owned subsidiary, ADC BioMedical Corp., has obtained a cannabis purchase/sales licence, with a provision to apply [...]

Research & development a primary focus for this medical cannabis company TORONTO, Aug. 15, 2019 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: "CANQF") (the "Company" or "CanaQuest"), announces it has been selected as a Global Awards Finalist by the International Trade Council. This invitation to the final judging panel will take place during the Think Global Conference on October 22nd and 23rd in Chicago USA. This recognition of CanaQuest opens doors for international business opportunities. CanaQuest will present before a world-famous judging panel and an audience of 500+ CEO's, Investors and Government Ministers and Ambassadors from 28 countries. CanaQuest is working primarily in the science of cannabis. The company is a Medicinal Products [...]